Co-crystals
AssigneeCereSpir Incorporated
InventorsDaniel G. Chain, Ronald Mueller
Life of this patent
Estimating the term…
Abstract
Co-crystals of itanapraced; methods of preparation of the co-crystals; uses of the co-crystals as APIs; formulations containing the co-crystals; uses of the co-crystals and formulations for prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries; and methods of prevention and treatment of neurodegeneration disorders, infections, dementias, inflammation, and injuries are described.
Claims21
A pharmaceutical formulation comprising a therapeutically effective amount of an AICD inhibitor, the AICD inhibitor being in a form of a co-crystal, the co-crystal comprising a crystal lattice comprising molecules of the AICD inhibitor and a coformer, the AICD inhibitor interacting nonionically with the coformer in the crystal lattice, the AICD inhibitor and the coformer being associated only by non-ionic and noncovalent bonds, wherein
- the coformer is not a solvent,
- the pharmaceutical formulation consists of the AICD inhibitor, the coformer, the crystal lattice, and an optional pharmaceutically acceptable excipient(s),
- the AICD inhibitor is itanapraced, and
- the coformer is selected from a group consisting of citric acid, nicotinamide, saccharin, and vanillin.
A pharmaceutical formulation comprising a therapeutically effective amount of an AICD inhibitor, the AICD inhibitor being in a form of a co-crystal, the co-crystal comprising a crystal lattice comprising molecules of the AICD inhibitor and a coformer, the AICD inhibitor interacting nonionically with the coformer in the crystal lattice, wherein the AICD inhibitor includes a carboxylic acid moiety and the coformer is a nonvolatile heterocyclic organic compound having a pyridinyl moiety, the AICD inhibitor and the coformer being associated only by non-ionic and noncovalent bonds, wherein
- the coformer is not a solvent,
- the AICD inhibitor is itanapraced,
- the coformer is nicotinamide,
- a stoichiometric ratio of itanapraced to nicotinamide is from about 0.8:1.2 to about 1.2:0.8, and
- the co-crystal comprises an X-ray Powder Diffraction Pattern (XRPD) with specific peaks, expressed in 2θ produced from a Cu radiation source (λ=1.54 Å after Ni filtering), at about 14.63°;
- 14.90°;
- 15.56°;
- 16.71°;
- 18.24°;
- 18.46°;
- 20.03°;
- 20.27°;
- 22.01°;
- 22.27°;
- 24.17°;
- 24.47°;
- 26.14°;
- 26.47°;
- 27.83°;
- 28.85°;
- 29.97°;
- 30.64°;
- 32.42°;
- 34.07°;
- and 39.14°, all +/−0.2 degrees 2θ.
A pharmaceutical formulation comprising a therapeutically effective amount of an AICD inhibitor, the AICD inhibitor being in a form of a co-crystal, the co-crystal comprising a crystal lattice comprising molecules of the AICD inhibitor and a coformer, the AICD inhibitor interacting nonionically with the coformer in the crystal lattice, wherein the AICD inhibitor includes a carboxylic acid moiety and the coformer is a nonvolatile heterocyclic organic compound having a pyridinyl moiety, the AICD inhibitor and the coformer being associated only by non-ionic and noncovalent bonds, wherein the coformer is not a solvent and wherein the AICD inhibitor is itanapraced, and the coformer is nicotinamide.
Dependencies are inferred from the claim text.